{"entity":{"id":"kimadia-iraq","kind":"institution","name":"KIMADIA, State Company for Marketing Drugs and Medical Appliances (Iraq)","aka":["KIMADIA","State Company for Marketing Drugs and Medical Appliances"],"tldr":"The Ministry of Health's central buyer, founded in 1964, which procures and distributes medicines and equipment for public hospitals and clinics across Iraq. In 2019 it secured 60% of the essential medicines it is responsible for, and a short budget is named as a main cause of shortages.","summary":"The 2021 Eastern Mediterranean Health Journal report on pharmaceutical regulation in Iraq describes KIMADIA, founded in 1964, as the agency responsible for procuring and distributing medicines, medical appliances and equipment to public hospitals and primary care in all 18 provinces. It is required to procure the level 1 medicines on the national essential medicines list; where it cannot, provincial health directorates and hospitals may buy level 2 and then level 3 alternatives, or buy essential medicines from the private sector. In 2019 KIMADIA procured 60% of the level 1 essential medicines, and the report names an insufficient budget as one of the main reasons for shortages of essential medicines over several decades. KIMADIA can negotiate prices below the registered price in its tenders; national manufacturers held 15.3% of the value and 47.8% of the volume of its contracts in 2019. Public outpatient prescriptions cost the patient between 0.8 and 2.5 US dollars, according to the same report. The coordinates are a Baghdad city point.","asOf":"2026-11-11","links":[{"label":"Al-Jumaili et al., Pharmaceutical regulations in Iraq (East Mediterr Health J 2021, PDF)","url":"https://applications.emro.who.int/EMHJ/V27/10/1020-3397-2021-2710-1007-1015-eng.pdf"}],"tags":[],"related":["global-oncology-access"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iraq-moh-technical-affairs","iraq-health-insurance-authority"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Baghdad","country":"IQ","lat":33.31,"lng":44.39,"institutionType":"government","programs":["Central procurement of level 1 essential medicines","Distribution to public health facilities in 18 provinces","Customs clearance of medicines at the federal level, with the Ministry of Trade"]},"route":"/institutions/kimadia-iraq/","neighbours":{"technology":[{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/"}],"institution":[{"id":"iraq-moh-technical-affairs","kind":"institution","name":"Directorate of Technical Affairs, Ministry of Health, Iraq (medicines regulator)","route":"/institutions/iraq-moh-technical-affairs/"},{"id":"iraq-health-insurance-authority","kind":"institution","name":"Health Insurance Authority (Iraq)","route":"/institutions/iraq-health-insurance-authority/"}],"paper":[{"id":"paper-al-jumaili-pharmaceutical-regulation-iraq-emhj-2021","kind":"paper","name":"Pharmaceutical regulation in Iraq, from medicine approval to post-marketing","route":"/key-papers/paper-al-jumaili-pharmaceutical-regulation-iraq-emhj-2021/"}]}}